Anne Gonzalez
Family Medicine · Hickory, NCNPI 1821030834
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $473 and has fallen 96.9% since, to $15 in 2025.
Across 88 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$294
- AbbVie$150
- Lupin Inc.$125
- Currax Pharmaceuticals LLC$100
- Merz North America, Inc.$98
- Lilly USA, LLC$87
- plus $570 from 24 others
What the payments were for
- Food & beverage$1,424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,424 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $65,640 |
| EliquisApixaban | 17 | $26,451 |
| Nurtec OdtRimegepant Sulfate | 24 | $24,114 |
| MounjaroTirzepatide | 13 | $17,074 |
| RybelsusSemaglutide | 17 | $15,591 |
| Repatha SureclickEvolocumab | 18 | $13,619 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,103 |
| MyrbetriqMirabegron | 11 | $9,466 |
| ElmironPentosan Polysulfate Sodium | 12 | $8,161 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $2,678 |
| SynthroidLevothyroxine Sodium | 31 | $2,205 |
| Bupropion XlBupropion Hcl | 40 | $1,026 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $974 |
| Duloxetine Hcl | 44 | $869 |
| Atorvastatin Calcium | 72 | $747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $294 | $81,23172 claims |
| PfizerEliquis, Nurtec Odt | $68 | $50,56641 claims |
| Lilly USA, LLCMounjaro | $87 | $17,07413 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $9,46611 claims |
| AbbVieSynthroid | $150 | $2,20531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Hickory
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.